Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL-018 (omalizumab) Autoinjector vs Pre-filled Syringe PK Study
NCT06929052Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omalizumab in asthma, chronic spontaneous urticaria (CSU) and nasal polyps (2 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Serum Concentration at 126 days, Area Under the Curve to the last measurable concentration at 126 days and 1 more. Started Jan 2025; status: completed.
02
Drugs
omalizumab
03
Conditions
asthmachronic spontaneous urticaria (CSU)nasal polyps
Beyond the preview
Go deeper on NCT06929052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929052.